Quince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) will likely be announcing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Quince Therapeutics to post earnings of ($0.2250) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $0.11 on Monday. The firm has a market capitalization of $5.93 million, a PE ratio of -0.09 and a beta of 1.28. Quince Therapeutics has a 1 year low of $0.09 and a 1 year high of $4.55. The firm’s fifty day simple moving average is $1.22 and its 200 day simple moving average is $1.93.

Wall Street Analysts Forecast Growth

QNCX has been the subject of a number of recent analyst reports. Lucid Cap Mkts cut shares of Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a report on Friday, January 30th. Maxim Group cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Citizens Jmp downgraded Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, January 30th. Citigroup lowered Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. Finally, D. Boral Capital downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $7.67.

Institutional Trading of Quince Therapeutics

A number of large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new position in Quince Therapeutics in the second quarter valued at about $4,172,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Quince Therapeutics during the fourth quarter worth approximately $7,538,000. Millennium Management LLC raised its stake in shares of Quince Therapeutics by 1,152.9% in the third quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock valued at $2,260,000 after acquiring an additional 1,276,094 shares during the last quarter. Superstring Capital Management LP bought a new position in shares of Quince Therapeutics in the fourth quarter valued at approximately $2,877,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Quince Therapeutics by 442.1% in the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock worth $1,263,000 after acquiring an additional 632,076 shares in the last quarter. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.